<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36862382</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2326-5205</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Arthritis &amp; rheumatology (Hoboken, N.J.)</Title><ISOAbbreviation>Arthritis Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Lupus Interference With B Cell Tolerance Across the Developmental Continuum.</ArticleTitle><Pagination><StartPage>1503</StartPage><EndPage>1505</EndPage><MedlinePgn>1503-1505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/art.42485</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pemberton</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Seattle Children's Research Institute, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Shaun W</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-7024-5252</Identifier><AffiliationInfo><Affiliation>Seattle Children's Research Institute and Departments of Pediatrics and Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AR073938</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR075813</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arthritis Rheumatol</MedlineTA><NlmUniqueID>101623795</NlmUniqueID><ISSNLinking>2326-5191</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="Y">B-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>2</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36862382</ArticleId><ArticleId IdType="mid">NIHMS1880904</ArticleId><ArticleId IdType="pmc">PMC10474238</ArticleId><ArticleId IdType="doi">10.1002/art.42485</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Elkon KB, Wiedeman A. Type I IFN system in the development and manifestations of SLE. Curr Opin Rheumatol. 2012;24(5):499&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">22832823</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Tsao BP. Updates in Lupus Genetics. Curr Rheumatol Rep. 2017;19(11):68.</Citation><ArticleIdList><ArticleId IdType="pubmed">28983873</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB. Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol. 2008;14(3):131&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743115</ArticleId><ArticleId IdType="pubmed">18525429</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020;382(3):211&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol. 2002;14(4):411&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11934877</ArticleId></ArticleIdList></Reference><Reference><Citation>Green NM, Laws A, Kiefer K, Busconi L, Kim YM, Brinkmann MM, et al. Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol. 2009;183(3):1569&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929820</ArticleId><ArticleId IdType="pubmed">19587008</ArticleId></ArticleIdList></Reference><Reference><Citation>Domeier PP, Chodisetti SB, Schell SL, Kawasawa YI, Fasnacht MJ, Soni C, et al. B-Cell-Intrinsic Type 1 Interferon Signaling Is Crucial for Loss of Tolerance and the Development of Autoreactive B Cells. Cell Rep. 2018;24(2):406&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6089613</ArticleId><ArticleId IdType="pubmed">29996101</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemazee D.Mechanisms of central tolerance for B cells. Nat Rev Immunol. 2017;17(5):281&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623591</ArticleId><ArticleId IdType="pubmed">28368006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zikherman J, Parameswaran R, Weiss A. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature. 2012;489(7414):160&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438375</ArticleId><ArticleId IdType="pubmed">22902503</ArticleId></ArticleIdList></Reference><Reference><Citation>Meffre E, O&#x2019;Connor KC. Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev. 2019;292(1):90&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9145185</ArticleId><ArticleId IdType="pubmed">31721234</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul E, Lutz J, Erikson J, Carroll MC. Germinal center checkpoints in B cell tolerance in 3H9 transgenic mice. Int Immunol. 2004;16(2):377&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734623</ArticleId></ArticleIdList></Reference><Reference><Citation>Du SW, Arkatkar T, Al Qureshah F, Jacobs HM, Thouvenel CD, Chiang K, et al. Functional Characterization of CD11c(+) Age-Associated B Cells as Memory B Cells. J Immunol. 2019;203(11):2817&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6864310</ArticleId><ArticleId IdType="pubmed">31636237</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancro MP. Age-Associated B Cells. Annu Rev Immunol. 2020;38:315&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">31986068</ArticleId></ArticleIdList></Reference><Reference><Citation>Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4959992</ArticleId><ArticleId IdType="pubmed">27088255</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell TM, Bansal AS, Shorthouse C, Sandford N, Powell EE. Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol. 1999;14(5):419&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10355504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>